TR
Markets Editor
Tom Reyes
Covers earnings, deals, financings and the public companies behind therapeutic peptides.
Beats: Markets, GLP-1 · 44 entries on the wire
Power Plate Launches RESET Collection Aimed at GLP-1 Medication Users
By Tom ReyesGLP-1 Companion Food Market Forecast to Hit $11.66 Billion by 2030
By Tom ReyesPrecedence Research Publishes Semaglutide Market Outlook Through 2035
By Tom ReyesPEPTI stays in compounded GLP-1s as larger platforms step back
By Tom ReyesPEPTI charges no membership fee as rivals stack monthly dues
By Tom ReyesNovo Nordisk signs Orbis Medicines discovery deal worth up to $1.4 billion
By Tom ReyesNovo Nordisk trims pipeline and rebrands amid obesity competition
By Tom ReyesCracker Barrel Falls 15.5% as GLP-1 Shift Hits Traffic
By Tom ReyesPlexusDx Details Cora Health Semaglutide Plan Costs and Fees
By Tom ReyesPlexusDx Compares Cheaper GLP-1 Providers Against Cora Health
By Tom ReyesPlexusDx Compares Seven GLP-1 Providers Against Trava Pricing
By Tom ReyesPlexusDx Outlines Cora Health Tirzepatide Pricing for 2026
By Tom ReyesPlexusDx Asks Whether Lavender Sky GLP-1 Costs Rise With Dose
By Tom ReyesPlexusDx Reviews Brello Health GLP-1 Dose-Based Pricing
By Tom ReyesPLU Laboratories Pledges Transparency Push for GHK-Cu Peptide Cosmetics
By Tom ReyesBenefits advisers outline considerations for employer GLP-1 coverage decisions
By Tom ReyesAnalysis argues Novo Nordisk shares trade 59% below fair value
By Tom ReyesNovo Nordisk stock posts worst week since February amid rebrand
By Tom ReyesAnalyst says Novo rebrand signals strategy shift, not just marketing
By Tom ReyesNovo Nordisk Turns to AI to Reshape Drug Discovery
By Tom ReyesSacramento Restaurant Adapts Menu as GLP-1 Use Curbs Appetites
By Tom ReyesVeritiv Launches TempSafe RxShield for GLP-1 Cold-Chain Shipping
By Tom Reyes
Lactalis Ingredients Targets Protein Bar Texture as GLP-1 Shifts Demand
By Tom ReyesPharmacy leader urges linking GLP-1 coverage to wellness program participation
By Tom ReyesAnalysts weigh Novo Nordisk's position as GLP-1 competition intensifies
By Tom ReyesWashington Post: GLP-1 weight-loss coverage may tighten for patients
By Tom ReyesHaleon US sales rise as company markets GLP-1 side-effect remedies
By Tom ReyesEli Lilly shares rise 3.2% to $1,139 in market quote
By Tom ReyesNovo Nordisk shares slip after rebrand to Novo draws analyst caution
By Tom ReyesEli Lilly accelerates acquisitions to diversify beyond weight-loss franchise
By Tom ReyesTelehealth Provider Levity Details Semaglutide Plan and Renewal Pricing
By Tom ReyesLevity Prices Branded Mounjaro Tirzepatide at $1,299 Monthly
By Tom ReyesNovo Nordisk Rebrands as Novo, Resets Corporate Operating Model
By Tom ReyesNavitus Launches GLP-1 Drug Management Programs for Payers
By Tom ReyesNovo Nordisk Shares Fall After Rebrand Meets Investor Skepticism
By Tom ReyesBerenberg sees 21% upside in Lilly ahead of EASD data
By Tom ReyesAnalysts weigh Novo Nordisk against Regeneron for 2026 investors
By Tom ReyesBerenberg says Mounjaro maker Lilly has further upside
By Tom ReyesAscendis regains full rights to TransCon metabolic programs from Novo
By Tom ReyesAnalysis Examines Novo Nordisk's Pivot Toward Obesity Market
By Tom ReyesAscendis Pharma Regains Rights to TransCon Semaglutide Program
By Tom ReyesBitcoin payments fuel $32M gray-market peptide trade
By Tom ReyesSamik Pharm jumps 16% on monthly thymosin alpha 1 patent
By Tom ReyesHims & Hers leans on testosterone as GLP-1 competition intensifies
By Tom Reyes